One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Diabetes, metformin and breast cancer: a tangled web
A.E. Lohmann, P.J. Goodwin
doi : 10.1016/j.annonc.2020.12.014
Volume 32, Issue 3, March 2021, Pages 285-286
Adjuvant radiotherapy for gastric cancer—end of the road?
F. Lordick, M. Nilsson, T. Leong
doi : 10.1016/j.annonc.2020.12.006
Volume 32, Issue 3, March 2021, Pages 287-289
Sentinel node biopsy for primary cutaneous melanoma
M.B. Faries, A.A.E. Testori, J.E. Gershenwald
doi : 10.1016/j.annonc.2021.01.007
Volume 32, Issue 3, March 2021, Pages 290-292
Follicular lymphoma: treatment guidance in times of change
C. Buske
doi : 10.1016/j.annonc.2021.01.001
Volume 32, Issue 3, March 2021, Pages 293-294
Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy
M. Sznol, I. Melero
doi : 10.1016/j.annonc.2020.11.018
Volume 32, Issue 3, March 2021, Pages 295-297
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling, M. Ghielmini, S. Rule, G. Salles, ... M. Jerkeman
doi : 10.1016/j.annonc.2020.11.008
Volume 32, Issue 3, March 2021, Pages 298-308
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M.A. Dimopoulos, P. Moreau, E. Terpos, M.V. Mateos, ... U. Mey
doi : 10.1016/j.annonc.2020.11.014
Volume 32, Issue 3, March 2021, Pages 309-322
Immunotherapy for early breast cancer: too soon, too superficial, or just right?
M.A. Franzoi, E. Romano, M. Piccart
doi : 10.1016/j.annonc.2020.11.022
Volume 32, Issue 3, March 2021, Pages 323-336
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
C. Belli, F. Penault-Llorca, M. Ladanyi, N. Normanno, ... G. Curigliano
doi : 10.1016/j.annonc.2020.11.021
Volume 32, Issue 3, March 2021, Pages 337-350
A prospective study of type 2 diabetes, metformin use, and risk of breast cancer
Y.-M.M. Park, D.B. Bookwalter, K.M. O'Brien, C.L. Jackson, ... D.P. Sandler
doi : 10.1016/j.annonc.2020.12.008
Volume 32, Issue 3, March 2021, Pages 351-359
Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial
W.O. de Steur, R.M. van Amelsfoort, H.H. Hartgrink, H. Putter, ... C.J.H. van de Velde
doi : 10.1016/j.annonc.2020.11.004
Volume 32, Issue 3, March 2021, Pages 360-367
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
S.H. Park, D.H. Lim, T.S. Sohn, J. Lee, ... W.K. Kang
doi : 10.1016/j.annonc.2020.11.017
Volume 32, Issue 3, March 2021, Pages 368-374
Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor
M.-A. El Sharouni, M.D. Stodell, T. Ahmed, K.P.M. Suijkerbuijk, ... S.N. Lo
doi : 10.1016/j.annonc.2020.11.015
Volume 32, Issue 3, March 2021, Pages 375-383
Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study
H. Gogas, B. Dréno, J. Larkin, L. Demidov, ... A. Arance
doi : 10.1016/j.annonc.2020.12.004
Volume 32, Issue 3, March 2021, Pages 384-394
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer
R. Perets, J. Bar, D.W. Rasco, M.-J. Ahn, ... B.C. Cho
doi : 10.1016/j.annonc.2020.11.020
Volume 32, Issue 3, March 2021, Pages 395-403
Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT
A.-S. Cottereau, M. Meignan, C. Nioche, N. Capobianco, ... I. Buvat
doi : 10.1016/j.annonc.2020.11.019
Volume 32, Issue 3, March 2021, Pages 404-411
The effect of age on the acquisition and selection of cancer driver mutations in sun-exposed normal skin
B. Hernando, M. Dietzen, G. Parra, M. Gil-Barrachina, ... C. Martinez-Cadenas
doi : 10.1016/j.annonc.2020.11.023
Volume 32, Issue 3, March 2021, Pages 412-421
Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
T. Powles, ESMO Guidelines Committee
doi : 10.1016/j.annonc.2020.11.016
Volume 32, Issue 3, March 2021, Pages 422-423
Key role for liquid biopsy in the elimination of breast cancer surgery following neoadjuvant therapy
A. Grinshpun, J. Moss, B. Uziely
doi : 10.1016/j.annonc.2020.12.002
Volume 32, Issue 3, March 2021, Page 423
Corrigendum to ‘Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases’: Annals of Oncology 2009; 20: 1136–1141
A.H. Aljubran, A. Griffin, M. Pintilie, M. Blackstein
doi : 10.1016/j.annonc.2020.12.011
Volume 32, Issue 3, March 2021, Page 424
